- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.10. | JPMorgan initiates Hemab Therapeutics stock with overweight rating | 2 | Investing.com | ||
| 12.10. | Rodman & Renshaw startet Coverage für Hemab mit Kaufempfehlung - Therapiepotenzial überzeugt | 3 | Investing.com Deutsch | ||
| 12.10. | Rodman & Renshaw initiates Hemab stock with buy on therapy potential | 1 | Investing.com | ||
| 24.09. | Hemab Therapeutics appoints Keli Walbert to board of directors | 1 | Investing.com | ||
| 24.09. | Hemab Therapeutics, Inc.: Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert | 209 | GlobeNewswire (Europe) | CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment... ► Artikel lesen | |
| HEMAB THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 24.09. | Hemab Therapeutics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.09. | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | 501 | GlobeNewswire (Europe) | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen | |
| 17.09. | Hemab Therapeutics, Inc.: Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding | 329 | GlobeNewswire (Europe) | Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecologists, with approximately 23 million seeking care... ► Artikel lesen | |
| 14.08. | Biotech Stocks At 52-Week Highs - Park Dental Partners +10%, Aveanna Healthcare +24%, Candel Therapeutics +10% on Q2 Reports, Labcorp Holdings, Hemab Therapeutics | 1.441 | AFX News | LONDON (dpa-AFX) - The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.Park... ► Artikel lesen | |
| 12.08. | H.C. Wainwright hebt Kursziel für Hemab Therapeutics auf 60 US-Dollar an | 2 | Investing.com Deutsch | ||
| 11.08. | Hemab Therapeutics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.08. | Biotech Stocks At 52-Week Highs - Delcath Systems +22% On Q2 Results, Alto Neuroscience, Hemab Therapeutics, Monopar Therapeutics, Nurix Therapeutics | 1.249 | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation.... ► Artikel lesen | |
| 14.07. | Hemab präsentiert Phase-2-Daten für Sutacimig und plant Phase-3-Studie | 2 | Investing.com Deutsch | ||
| 14.07. | Hemab presents phase 2 data for sutacimig, plans phase 3 trial | 1 | Investing.com | ||
| 14.07. | Hemab Therapeutics, Inc.: Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress | 1 | GlobeNewswire (USA) | ||
| 13.07. | Hemab Advances Bleeding Disorder Pipeline | 3 | Benzinga.com | ||
| 13.07. | Hemab Therapeutics stock price target raised to $52 by H.C. Wainwright on trial data | 1 | Investing.com | ||
| 12.07. | Hemab Therapeutics, Inc.: Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress | 3 | GlobeNewswire (USA) | ||
| 10.07. | Gubra A/S: Gubra collaboration partner Hemab to present preclinical results for HMB-003, a potential treatment for multiple bleeding disorders, at the ISTH 2026 Congress | 488 | GlobeNewswire (Europe) | Copenhagen, July 10, 2026: Gubra's collaboration partner Hemab will present preclinical results from the HMB-003 program on July 11, 2026, at the ISTH Congress in Paris.
The preclinical data show that... ► Artikel lesen | |
| 26.06. | Hemab Therapeutics: Positive Studiendaten und Pipeline-Erweiterung treiben Aktie an | 1 | Investing.com Deutsch |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 420,35 | -0,20 % | Total Energy, ACT, Amgen at 52-Week Highs on News | ||
| BIOGEN | 224,70 | +0,36 % | BioNTech, Formycon, Biogen - Pharma-Milliarden werden neu verteilt | Die Pharmaindustrie steht vor einer gewaltigen Neuordnung. Während milliardenschwere Blockbuster-Medikamente ihre Patentexklusivität verlieren, drängen günstigere Nachahmer-Präparate auf den Markt.... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 739,00 | +0,37 % | Regeneron Extends BARDA Agreement For Additional Ebola Treatment Supply | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced an extension of its agreement with the U.S. Biomedical Advanced Research and Development Authorities (BARDA) to provide additional... ► Artikel lesen | |
| CELLDEX THERAPEUTICS | 26,400 | -1,46 % | Celldex Therapeutics, Inc.: Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints | Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab's potential to be a transformational therapy in CSUEMBARQ-CSU1 and -CSU2 met primary and all key secondary... ► Artikel lesen | |
| ARGENX | 803,20 | +0,75 % | Hohe Forschungs- und Verkaufskosten: Argenx verdient weniger als gedacht | AMSTERDAM (dpa-AFX) - Das Muskelschwäche-Medikament Vyvgart gibt dem Biotechspezialisten Argenx weiterhin mächtig Schub. Im dritten Quartal kletterte der Konzernumsatz im Jahresvergleich um mehr als... ► Artikel lesen | |
| REVOLUTION MEDICINES | 169,75 | 0,00 % | Could Revolution Medicines Be a Millionaire-Maker Stock? | ||
| INSMED | 100,30 | +0,92 % | Insmed Inc Q3 Loss Narrows | WASHINGTON (dpa-AFX) - Insmed Inc (INSM) revealed Loss for third quarter of -$100.32 millionThe company's earnings came in at -$100.32 million, or -$0.46 per share. This compares with -$370.02... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 86,50 | +0,58 % | H.C. Wainwright reiterates Oruka Therapeutics stock rating on trial data | ||
| KRYSTAL BIOTECH | 292,80 | +0,69 % | Krystal Biotech, Inc.: Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026 | ||
| SUMMIT THERAPEUTICS | 16,200 | 0,00 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| ULTRAGENYX | 14,915 | -0,77 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| SCHOLAR ROCK | 39,380 | 0,00 % | Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan | Under FDA guidance, Scholar Rock has successfully removed Catalent Indiana LLC (part of Novo Nordisk) as a commercial fill-finish facility from apitegromab Biologics License Application (BLA)... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 133,00 | -2,21 % | Palvella jumps as lead asset gets FDA priority review | ||
| IMMUNOCORE | 29,200 | +4,29 % | Immunocore Holdings plc: Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting | ||
| VAXCYTE | 56,00 | 0,00 % | Vaxcyte (NDQ:PCVX): Challenging The Pfizer-Merck Duopoly in the Lucrative Pneumococcal Space |
HEMAB THERAPEUTICS HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 40,425 Euro und damit +0,01 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEMAB THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.